This study is exploring new treatments for locoregional hepatocellular carcinoma (HCC), a type of liver cancer. The study includes a treatment called transarterial chemoembolization (TACE), combined with medications: durvalumab and tremelimumab. Some patients will also receive lenvatinib. TACE is a procedure where chemotherapy is delivered directly to the liver tumor. This study is for patients whose liver cancer cannot be cured with surgery or transplantation. Treatments like durvalumab and tremelimumab are drugs that help the immune system fight cancer.

• The study lasts for several months and involves multiple visits to the clinic.
• Participants may receive compensation for their time and travel.
• Risks may include side effects from treatments like fatigue or liver issues.

To participate, patients must have cancer only in the liver (and not spread elsewhere), be in good overall health, and have a specific liver function score called the Child Pugh score class A. If you have heart problems or high blood pressure that isn't controlled, you might not be eligible.